May 05, 2025

New Chikungunya Vaccine Shows Strong Response

A new single-dose chikungunya vaccine produced strong immune responses in nearly all adolescents and adults in a large clinical trial, with mild and short-lived side effects.

Conexiant

May 02, 2025

Psychotherapy, Family Tied to Better Outcomes

In a large meta-analysis, researchers identified the most effective components of collaborative care for treating depression in primary care.

Conexiant

May 02, 2025

CRP in CSF Accurately Detects Meningitis, Study 

CRP in cerebrospinal fluid showed high accuracy in diagnosing bacterial meningitis, helping doctors detect cases even when standard CSF markers appear normal.

Conexiant

May 01, 2025

Conservative Caries Management to Preserve Tooth Structure

Sealants and specialty burs enable minimally invasive treatment for incipient and developed lesions

Inside Dentistry

May 01, 2025

Myopia: Spectacle Lens Use

While these spectacle lenses are not yet approved by the US Food and Drug Administration, it’s likely a nod from the organization is not too far off. As a result, discussing the factors that influence treatment success makes sense.

Optometric Management

May 01, 2025

Contact Lenses: Comanaging Corneal Crosslinking

With the proven track record of epi-off corneal crosslinking (CXL) in halting keratoconus (KCN) progression and the forthcoming availability of epi-on CXL, let’s discuss the specific steps optometrists should take in comanaging these patients.

Optometric Management

April 30, 2025

Childhood Wheeze May Be Tied to Ozone Levels

Early-life ozone exposure was linked to increased odds of asthma and wheeze in children aged 4 to 6 years.

Conexiant

April 30, 2025

New Phase III Data on Brensocatib Therapy

Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant